Xsensio Raises Oversubscribed $7 Million Series A to Accelerate Continuous Biosensing Innovation
Swiss deep-tech firm pushes forward clinical adoption of wearable biochemical monitoring
LAUSANNE, Switzerland, March 5 — Swiss deep-tech company Xsensio SA has secured $7 million in an oversubscribed Series A funding round, providing a significant boost to its efforts to bring continuous biochemical monitoring technology into real-world healthcare environments.
The investment round was led by San Francisco-based venture capital firm WI Harper, with participation from Privilège Ventures, the European Innovation Council, and several private investors from the United States, Europe and Asia.
The company said the newly raised capital will be used to accelerate the development and clinical validation of its wearable biosensing platform known as Lab-on-Skin©.
This innovative technology enables the continuous monitoring of multiple biochemical biomarkers simultaneously in near real time, offering clinicians valuable physiological data that can support faster and more informed medical decisions.
Xsensio chief executive officer Esmeralda Megally said the successful Series A financing marks a critical milestone in the company’s mission to integrate continuous biochemical monitoring into everyday clinical practice.
According to her, the platform introduces a new level of insight into patient health by providing continuous biochemical data directly at the point of care.
“For the first time, clinicians can access key biochemical information in real time, data that has historically been unavailable during clinical decision-making,” she said.
Such access to continuous data, she added, could significantly improve the monitoring and treatment of patients by allowing healthcare professionals to respond quickly to physiological changes.
In addition to the funding announcement, Xsensio also revealed a long-term strategic collaboration with global semiconductor leader Texas Instruments.
The partnership will leverage Texas Instruments’ expertise in CMOS integration, device miniaturisation and scalable semiconductor manufacturing.
Xsensio chief technology officer Adrian Ionescu said the collaboration will strengthen the company’s technological roadmap and accelerate the development of scalable biosensing solutions.
By combining Xsensio’s biosensing innovations with Texas Instruments’ advanced semiconductor capabilities, the company aims to build a platform capable of delivering reliable and cost-effective health monitoring technologies.
“This partnership reinforces our ability to create advanced biosensing systems designed for both clinical impact and scalable deployment,” he said.
WI Harper partner Wilson Wu said the firm believes Xsensio is shaping a new category within the wearable biosensing industry.
Given the company’s strong technological progress and promising market potential, Wu said WI Harper was pleased to lead the investment round.
Meanwhile, Xsensio board chair Jaqueline Ruedin Rüsch described continuous biochemical monitoring as a transformative shift in healthcare technology.
She noted that the approach replaces traditional intermittent testing methods with real-time biochemical insights, enabling a more proactive and responsive approach to patient care.
According to her, Xsensio is well positioned to play a leading role in this transformation as the demand for advanced digital health technologies continues to grow worldwide.
-wilayah.com.my
